Combination immunotherapy improves outcomes for patients with non-small cell lung cancer
The phase 2 clinical trial of a multi-centre study known as the COAST clinical trial…
Browsing: Featured
Wireless device to provide new options for colorectal cancer treatment
For those diagnosed with colorectal cancer, surgery has been the only option that offers a…
New factors that can predict breast cancer recurrence defined
Genetics and other factors that can determine if a woman is at risk for a…
The OJC Meets YOGA
What issues inspire young oncologists in Australia today? What are their greatest challenges and hopes…
NHMRC annual awards celebrate excellence in Australian health and medical research
NHMRC’s annual awards recognising excellence in health and medical research were announced this evening in…
Updated guidelines prepare health professionals for cervical screening ‘game-changer’
Updated national cervical cancer clinical guidelines now provide the latest advice on the expanded eligibility…
The OJC 64: Going Dutch with Pancreatic Cancer and DRUP
In today’s episode Craig talks us through a Dutch study on Neoadjuvant Chemoradiotherapy in pancreatic…
Prostate cancer linked to bacteria, raising hope of new test and treatment
Rachel Hurst, University of East Anglia; Colin Cooper, University of East Anglia, and Jeremy Clark,…
Study reveals male sex hormones are new targets for cancer immunotherapy
Patients with cancers stemming from non-reproductive organs, such as bladder and liver cancer, have striking…
Protected: PBS listing for BRAFTOVI® (encorafenib) + cetuximab for metastatic colorectal (bowel) cancer patients with a BRAFV600 mutation(1)
This content is password-protected. To view it, please enter the password below. Password: